The study, published in Supportive Care in Cancer, was led by Syed E. Pasha of the University of Houston and HCA Houston Healthcare Kingwood, together with colleagues from MountainView Hospital and Texas Oncology centers. The team set out to answer a deceptively simple question: do patients with diffuse large B-cell lymphoma, an aggressive and rapidly treated lymphoma, experience different kidney outcomes than patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, an indolent disease that often smolders for years before requiring therapy? Comparative renal data between these two populations had been scarce, despite the fact that both cancers are common and both are treated with regimens known to stress the kidneys.

To answer the question, the researchers turned to the TriNetX Global Collaborative Network, a federated database drawing de-identified electronic health records from 143 healthcare organizations. Data were extracted on May 9, 2025. Adults with a coded diagnosis of diffuse large B-cell lymphoma or of chronic lymphocytic leukemia and small lymphocytic lymphoma were identified using standard ICD-10 diagnostic codes. To make the two groups as comparable as possible, the investigators used a statistical technique called propensity score matching, pairing each patient with a counterpart from the other cohort who shared the same age, sex, race, and ethnicity. This one-to-one matching produced two demographically indistinguishable groups, with standardized mean differences between them ranging from just 0.001 to 0.038, values so small they indicate near-perfect balance.

The final analysis included 19,438 patients, evenly split with 9,719 in each cohort. Kidney outcomes were tracked from the first day after the index diagnosis through each patient’s available follow-up, an open-ended window rather than a fixed observation period. The researchers looked for two distinct conditions: acute kidney injury, the sudden loss of renal function that can develop within hours or days, and chronic kidney disease, the gradual, often irreversible decline in filtration capacity that unfolds over months and years. Statistical comparisons relied on two-proportion z-tests, generating risk differences, risk ratios, and odds ratios with 95 percent confidence intervals.

The results revealed a fascinating split. Acute kidney injury struck 22.9 percent of the diffuse large B-cell lymphoma patients compared with 20.9 percent of the chronic lymphocytic leukemia and small lymphocytic lymphoma group. That two-percentage-point gap was statistically significant, with a risk ratio of 1.094 and an odds ratio of 1.122, and a p-value of 0.001. In other words, the aggressive lymphoma carried a modestly higher risk of sudden renal failure. The pattern flipped for chronic kidney disease. Here, 18.8 percent of the lymphoma patients developed the condition versus 22.7 percent of the leukemia and indolent lymphoma group, a negative risk difference of 4.0 percent, with a risk ratio of 0.825 and an odds ratio of 0.785, and a p-value below 0.001. The slower cancer, paradoxically, left a heavier mark on long-term kidney health.

The biology behind this divergence makes intuitive sense when one considers how each disease and its treatment unfold. Diffuse large B-cell lymphoma grows quickly and is typically treated with intensive chemoimmunotherapy, most commonly regimens built around rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone. Rapid tumor cell death can trigger tumor lysis syndrome, a cascade in which potassium, phosphate, and uric acid flood the bloodstream and crystallize in renal tubules, a well-documented cause of acute kidney injury. High-dose chemotherapy agents themselves, along with the infections, dehydration, and intensive care admissions that can accompany aggressive treatment, all add to the short-term renal assault.

Chronic lymphocytic leukemia, by contrast, is a disease of accumulation and time. Patients frequently live with it for a decade or more, and even those who never require treatment face aging kidneys, cumulative exposure to nephrotoxic drugs across successive lines of therapy, and immune complications. Modern targeted therapies such as ibrutinib, which has transformed outcomes in this disease, carry their own renal baggage; real-world analyses of hundreds of treated patients have documented a spectrum of toxicities that can include hypertension and kidney dysfunction. Over years of surveillance, treatment, and comorbidity, the indolent disease’s patient population gradually accrues the chronic damage that shows up as chronic kidney disease. The new data, showing a 22.7 percent chronic kidney disease rate in this group, align with that clinical picture.

The authors are careful to frame their findings as hypothesis-generating rather than definitive. The matching algorithm balanced demographics but did not capture comorbidities such as diabetes, hypertension, or pre-existing renal impairment, all of which are powerful drivers of kidney disease and may differ systematically between the two cancer populations. Follow-up duration was also not matched, and the open-ended observation window means patients in one group may simply have been watched longer. Absolute differences between the cohorts were small, in the range of two to four percentage points, and the study relied on administrative diagnostic codes rather than laboratory-verified kidney function measures. The research was supported in whole or in part by HCA Healthcare, though the authors declare no competing interests, and the views expressed are those of the authors alone.

Even with those caveats, the study carries practical weight for the growing field of onco-nephrology, the discipline that sits at the intersection of cancer care and kidney medicine. Acute kidney injury in patients with hematological malignancies is known to worsen remission rates and survival, and chronic kidney disease constrains which cancer therapies a patient can safely receive, since many agents require dose adjustment or are contraindicated in renal impairment. If the pattern observed here holds up, supportive care pathways might reasonably emphasize vigilant short-term renal monitoring, hydration protocols, and uric acid management around the intensive treatment phases of aggressive lymphoma, while building durable long-term nephrology follow-up into the care of chronic lymphocytic leukemia survivors, whose kidneys face a marathon rather than a sprint.

What comes next is confirmation. The authors themselves call for comorbidity-adjusted analyses and prospective studies to verify whether the renal risk differences survive when diabetes, hypertension, baseline kidney function, and treatment exposure are properly accounted for. Until then, the message for clinicians is one of heightened awareness rather than alarm: both cancer subtypes deserve deliberate attention to the kidneys, but the timing and nature of that attention may need to differ. A single dataset of nearly twenty thousand matched patients cannot settle every question, but it has usefully drawn a map, pointing oncologists toward the moments in each disease trajectory where the kidneys are most vulnerable, and reminding the wider medical community that surviving cancer is only half the story, with protecting the organs that carry patients through survivorship being the other half.

Subject of Research: Comparative renal outcomes of acute kidney injury and chronic kidney disease in diffuse large B-cell lymphoma versus chronic lymphocytic leukemia/small lymphocytic lymphoma

Article Title: Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care

Article References: Pasha, S. E., Khalique, S., Haddadin, R., Mazharuddin, S., & Khoury, P. N. (2026). Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care. Supportive Care in Cancer, 34(10), Article 1029. https://doi.org/10.1007/s00520-026-11256-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11256-y

Keywords: diffuse large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, acute kidney injury, chronic kidney disease, supportive oncology, onco-nephrology, nephrotoxicity, TriNetX, propensity score matching, real-world data, tumor lysis syndrome

The historical record explains why skepticism took root. Studies conducted in the 1980s and 1990s reported in-hospital mortality approaching 90 percent among patients with acute myeloid leukemia who required invasive mechanical ventilation. Against such figures, many clinicians questioned whether intensive care offered anything more than a prolonged and painful death. Yet the evidence landscape has steadily transformed. Refinements in patient selection, combined with sweeping advances in supportive care, have progressively improved outcomes, and more recent studies report in-ICU mortality rates of approximately 45 percent for critically ill patients with acute leukemia. That trajectory, from near-certain fatality to a coin-flip chance of survival, represents one of the quiet revolutions in hematology and intensive care.

A major new analysis has now brought unprecedented statistical weight to this transformation. An individual participant data meta-analysis by Chean and colleagues, published in Intensive Care Medicine, examines the outcomes of critically ill adults with acute leukemia using data from 2,003 patients treated in 55 intensive care units across 19 countries, with an inclusion period spanning more than two decades, from January 2000 to July 2023. The scale and duration of the study fill a long-standing knowledge gap created by earlier single-center investigations and limited sample-size analyses that focused mainly on patients younger than 60 years, a group that no longer reflects the real-world demographics of the disease.

What distinguishes this meta-analysis methodologically is its use of the individual participant data approach. Unlike conventional meta-analyses that rely on aggregated results extracted from published papers, an IPD meta-analysis goes back to the raw data of each contributing study and reanalyzes them. This allows researchers to improve both the quantity and quality of the evidence, to include information that was never reported in the original publications, and to standardize analyses and outcome definitions across studies. The method demands that investigators contact the corresponding author of every included trial or cohort, an arduous process that explains why such analyses remain relatively rare but carry exceptional authority when completed.

The findings confirm what many specialists hoped but could not previously prove with such rigor: ICU mortality has decreased over time among patients requiring mechanical ventilation. The authors of the accompanying editorial, Guillaume Berton and Norbert Vey of Aix-Marseille University and Institut Paoli-Calmettes in Marseille, attribute this trend to improvements on two fronts simultaneously. On the hematology side, new chemotherapy regimens have emerged, while supportive care has advanced dramatically through antimicrobial prophylaxis and improved management of febrile neutropenia, the dangerous fever that strikes patients whose infection-fighting white cells have been wiped out by both disease and treatment.

Perhaps the most striking demographic shift documented in the analysis is the changing age profile of patients reaching the ICU. The proportion of patients older than 65 years admitted to intensive care nearly doubled over the study period, rising from 18 percent before 2010 to 33 percent after 2010. This is not a coincidence of referral patterns but a direct consequence of therapeutic innovation. For decades, elderly patients with acute leukemia were often offered palliative care because intensive cytotoxic chemotherapy, the gold standard for younger patients, was considered too toxic for bodies with diminished functional reserves. That paradigm has been upended by non-intensive approaches, most notably the combination of hypomethylating agents with the BCL-2 inhibitor venetoclax, which has demonstrated a median overall survival of 14.7 months and has become the standard of care for AML patients ineligible for intensive chemotherapy.

The therapeutic revolution extends further. Although the Chean meta-analysis excluded post-transplant ICU admissions, advances in allogeneic stem-cell transplantation now allow this potentially curative procedure to be offered to increasingly older patients, with evidence supporting matched sibling, unrelated, and haploidentical donor options in those over 60. Together, these developments signal that treatment for older AML patients has moved decisively from palliative approaches to strategies with curative intent, and the resulting lengthening of survival will only reinforce the role of intensive care in this population. But with more therapeutic possibilities come new dilemmas, above all patient selection, which must rest on a careful evaluation of frailty and is tightly interwoven with the triage decisions made before ICU admission is even offered.

The meta-analysis also delivered a finding that unsettles prior assumptions: older age, defined as above 65 years, emerged as an adverse predictor of in-ICU mortality. This contrasts with earlier studies that had reported in-ICU mortality rates for elderly patients similar to those of younger cohorts. The editorial authors suggest the discrepancy may reflect variable levels of expertise among the participating centers, illustrated by differences in outcomes according to the national economic level of the countries involved. Such disparities may influence not only the quality of intensive care management but also which patients are selected for admission in the first place, raising uncomfortable questions about equity of access to critical care for older patients with leukemia.

The stakes of that triage question are amplified by what happens after patients leave the unit. A recent report highlighted in the editorial found that a significant proportion of AML patients require modifications to their antileukemic treatment following ICU discharge, altering their long-term prognosis, with older age increasing this risk. In other words, the ICU episode does not exist in isolation; it can derail the optimal cancer therapy on which survival ultimately depends. Conversely, one important limitation of the Chean analysis is that treatment response was not considered, even though response is a major determinant of survival and of the success of organ failure management. Future studies, the editorial argues, should incorporate modern response criteria, including the residual disease assessments now routinely used in hematology practice.

Finally, the editorial closes with a human dimension that data alone cannot capture: patients’ own wishes. Goals-of-care discussions are key to determining the most appropriate management strategy for critically ill patients with cancer, yet they remain relatively infrequent in practice, a gap that demands further research. Meanwhile, the treatment landscape continues to accelerate. More potent antileukemic agents are inducing deeper and longer responses, but each advance carries novel toxicities: venetoclax can trigger tumor lysis syndrome, targeted molecular therapies against FLT3, IDH, and menin can provoke differentiation syndrome causing respiratory, hemodynamic, and renal failure, and the spread of immunotherapy brings risks exemplified by cytokine release syndrome and immune cell-associated neurotoxicity seen with T-cell engagers and CAR T cells in acute lymphoblastic leukemia. As these therapies expand, the editorial concludes, more than ever a continuous close collaboration between intensivists and hematologists is paramount to ensure proper management of these increasingly complex, increasingly survivable patients.

Subject of Research: Intensive care unit access and outcomes for critically ill adults with acute leukemia

Article Title: Beyond classical boundaries: rethinking ICU access in acute leukemia

Article References: Berton, G., & Vey, N. (2026). Beyond classical boundaries: rethinking ICU access in acute leukemia. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08623-y

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08623-y

Keywords: acute leukemia, intensive care unit, acute myeloid leukemia, ICU mortality, mechanical ventilation, venetoclax, hypomethylating agents, allogeneic stem-cell transplantation, tumor lysis syndrome, individual participant data meta-analysis, elderly patients, goals of care